| NCT ID | NCT04323904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Cologne |
| Condition | Hantavirus Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-03-04 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2020-03-04 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hantavirus disease are zoonotic infections and remain a clinical challenge with globally increasing incidence and multiple serious outbreak situations in Europe within the last years. Hantavirus disease encompasses two clinical syndromes, hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS) caused by Old World and New World hantaviruses, respectively. Depending on the causative Old World hantavirus species, clinical course of HFRS can vary from mild to moderate to severe. At present, there is no specific therapy available for hantavirus disease. As the clinical course of hantavirus disease is dependent on the causing viral pathogen and as there worrisome hints that clinical course HFRS and HCPS overlap, further studies with regard to the disease course are mandatory. Furthermore, the examination of attributable mortality and costs of hantavirus disease will need to be studied on a multinational basis and therefore HantaReg will particularly use a matched case control design.
Eligibility Criteria
Inclusion Criteria: * Serological or molecular evidence of hantavirus infection and clinical evidence of nephropathia epidemica or hemorrhagic fever with renal syndrome (HFRS) * Serological or molecular evidence of hantavirus infection and clinical evidence of hantavirus cardiopulmonary syndrome (HCPS) Exclusion Criteria: \- Serological or molecular evidence of hantavirus infection without clinical signs of nephropathia epidemica, HFRS or HCPS
Contact & Investigator
Volker Burst, MD
PRINCIPAL INVESTIGATOR
University Hospital of Cologne
Frequently Asked Questions
Who can join the NCT04323904 clinical trial?
This trial is open to participants of all sexes, studying Hantavirus Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04323904 currently recruiting?
Yes, NCT04323904 is actively recruiting participants. Contact the research team at felix.koehler@uk-koeln.de for enrollment information.
Where is the NCT04323904 trial being conducted?
This trial is being conducted at Cologne, Germany.
Who is sponsoring the NCT04323904 clinical trial?
NCT04323904 is sponsored by University of Cologne. The principal investigator is Volker Burst, MD at University Hospital of Cologne. The trial plans to enroll 200 participants.